Dubai, United Arab Emirates: October 17, 2011: Hundreds of healthcare professionals from across the Gulf have gathered in Dubai to take part in the UAE's third fully comprehensive cancer congress, which covered presentations on a wide range of diseases including breast cancer, lung cancer, gastro-intestinal cancer, liver cancer, blood cancer and bone health.
NewBridge Pharmaceuticals FZ LLC participated at the UAE Cancer Congress which took place from 6-8 October 2011 in Dubai. The congress in its third year was sponsored by major pharmaceutical companies and had more than 50 participants representing every specialty involved in the treatment of patients suffering from cancer. The NewBridge booth drew a large number of visitors, Oncologists and Key Opinion Leaders from the region who showed their enthusiasm towards its innovative products for cancer patients care.
Mr. Joe Henein, President and CEO of NewBridge Pharmaceuticals said, “It is very exciting for NewBridge to participate in this comprehensive cancer congress and meet physicians working with cancer patients in the entire Middle East and GCC region. NewBridge is pioneering in personalized medicine area and taking a multidisciplinary approach to cancer detection and treatment management, and we are extremely proud to show our support by bringing innovative products to address the unmet medical needs for the cancer patients in our region”.
Overall, the UAE Cancer Congress, with its theme, “Promoting Excellence in Oncology”, has proven to be a great success for NewBridge and has witnessed the beginning of multiple cooperation and partnership opportunities.
------- End -------
About NewBridge Pharmaceuticals:
Based in Dubai, UAE, NewBridge is a specialty pharmaceutical, biologics, medical devices company serving the emerging markets of Africa, Middle East, Turkey, and Caspian regions (collectively, AfMET) to address the unmet medical needs in diseases with high regional prevalence such as cancer, diabetes, renal and cardiovascular diseases and other metabolic disorders. NewBridge in-licenses and commercializes FDA and EMA/European and Japanese -approved therapeutics. NewBridge is led by an experienced management team and backed by top-tier investors including Burrill& Company and the National Technology Enterprises Company.